PathogenDx, Inc., a Scottsdale, Arizona-based DNA-based pathogen testing company, raised $7.5m in Series B funding.
The round was led by Cresco Capital Partners with participation from Altitude Investment Management, Arcadian Investment Partners, Panther Opportunity Fund LLC, Salveo Capital, Flatiron Venture Partners and other investors.
The company intends to use the funds to continue:
– expanding its technology into food and agriculture testing, while
– building on its position with current portfolio of domestic and international clients in the cannabis industry.
Led by CEO Milan Patel, PathogenDx provides DNA-based testing through adoption of its advanced microarray testing platform for the cannabis, hemp, agriculture, food and beverage industries. The company’s technology can identify and detect up to 50 pathogens all in a single test, in 6 hours providing triplicate data per analyte for certainty in results with a simple and easy process.
PathogenDx’ DNA-testing products – DetectX™, QuantX™, and EnviroX™– identify, detect and quantify pathogens like E. Coli, Salmonella and Aspergillus.